No price history available for this symbol yet.
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Sector
Drug Manufacturers - Specialty & Generic
Medicamen Biotech Limited, established in 1993 and headquartered in New Delhi, India, is an Indian pharmaceutical firm primarily engaged in the manufacturing and distribution of a diverse range of medicinal formulations. Its product line encompasses various dosage formats, including tablets, capsules, liquid and dry syrups, and topical ointments. The company further extends its portfolio to specialized items such as oral rehydration solutions, mouthwashes, and dental care products.
www.medicamen.comNo one on the platform currently holds MEDICAMEQ.NS.
No tracked institution reports a position in MEDICAMEQ.NS as of their last filing.
No one on the platform has traded MEDICAMEQ.NS yet.
Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.
Consensus does not cover every selected forecast year. Later assumptions are extrapolated from available analyst estimates.
| Metric | Historical average | My assumptions | ||||
|---|---|---|---|---|---|---|
| 1 year | 5 years | 10 years | Low | Mid | High | |
| ROIC % | 3.5% | 8.0% | 9.7% | — | — | — |
| Rev. Growth % | 21.7% | 11.9% | ||||
| Profit Margin % | 4.9% | 7.8% | 8.5% | |||
| Free Cash Flow Margin % | -20.1% | -9.5% | -9.2% | |||
| Exit P/E | — | — | — | |||
| Exit P/FCF | — | — | — | |||
| Desired Annual Return % | — | — | — | |||
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2027 | $1.3B | +16.4% | $11.64 | $11.64–$11.64 | — | 1 |
| 2028 | $1.4B | +10.1% | $12.34 | $12.34–$12.34 | — | 1 |
| 2029 | $1.7B | +15.0% | $14.71 | $14.71–$14.71 | — | 1 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
Beat consensus in 0 of the last 6 reported quarters
| Reported | Est. EPS | Actual | Surprise |
|---|---|---|---|
| 2026-02-09 | $3.50 | $1.61 | -54.0% |
| 2025-11-12 | $3.50 | $1.56 | -55.4% |
| 2025-08-12 | $3.50 | $1.18 | -66.3% |
| 2025-05-30 | $3.50 | $1.90 | -45.7% |
| 2025-02-11 | $3.50 | $2.30 | -34.3% |
| 2024-11-14 | $3.50 | $1.15 | -67.1% |
| Symbol | Price | Today | Mkt cap | P/E |
|---|---|---|---|---|
| MEDICAMEQ.NSMedicamen Biotech Limited | $345.50 | +8.58% | $4.7B | — |
| ALBERTDAVD.NSAlbert David Limited | $860.45 | +1.00% | $4.9B | — |
| BAFNAPH.NSBafna Pharmaceuticals Limited | $309.00 | +0.55% | $7.3B | — |
| KILITCH.BOKilitch Drugs (India) Limited | $186.30 | -0.11% | $6.6B | — |
| KILITCH.NSKilitch Drugs (India) Limited |
| $188.82 |
| -0.73% |
| $6.6B |
| — |
| MEDICO.BOMedico Remedies Limited | $35.48 | -1.09% | $3.0B | — |
| MEDICO.NSMedico Remedies Limited | $35.33 | -0.98% | $2.9B | — |
Source: Financial Modeling Prep · peers by sector/industry